Alaunos Therapeutics Receives Formal Nasdaq Delisting Notice for Equity Deficiency

summarizeSummary

Alaunos Therapeutics received a formal notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, initiating a process that could lead to delisting.

check_boxKey Events

• Nasdaq Delisting Notice Received

  On April 9, 2026, Alaunos Therapeutics received a formal notice from Nasdaq's Listing Qualifications Department.

• Non-Compliance with Equity Rule

  The company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. Its Annual Report on Form 10-K for fiscal year 2025 reported stockholders' equity of $2,153,000.

• Failure to Meet Alternative Standards

  Alaunos Therapeutics also fails to meet alternative continued listing standards, including a $35 million market value of listed securities or $500,000 in net income.

• Deadline for Compliance Plan

  The company has 45 calendar days (until May 26, 2026) to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days.

auto_awesomeAnalysis

Alaunos Therapeutics has received a formal notice from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement, a critical development following the 'going concern' warning in its recent 10-K. The company's reported equity of $2.153 million falls below the $2.5 million minimum, alongside failing other listing standards. This formal notice escalates the delisting risk, requiring the company to submit a compliance plan within 45 days. Failure to regain compliance could lead to the suspension or delisting of its shares, posing a significant threat to investor liquidity and the company's ability to raise capital, especially given its already precarious financial position and limited cash runway into Q2 2026.